Novartis's Kisqali Gains Traction In Pre-Menopausal Patients
Executive Summary
Top-line Phase III data from the MONALEESA-7 study could lead to an extension of Kisqali's indications into pre-menopausal women with a certain type of breast cancer, helping it gain traction in the highly competitive CDK4/6 inhibitor market.
You may also be interested in...
Pfizer Says Big Deals Create Value & 10 Other Notable Q3 Moments
Pfizer's third quarter earnings call covered a lot of ground, from pipeline updates, management's latest thinking on M&A, and strategic options for consumer healthcare, to industry trends like Amazon entering the drug distribution arena.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.